Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2017 Jan 3;116(1):36-43.
doi: 10.1038/bjc.2016.387. Epub 2016 Nov 29.

Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy

F Grossi  1 , E Rijavec  1 , C Genova  1 , G Barletta  1 , F Biello  1 , C Maggioni  1 , G Burrafato  1 , C Sini  1 , M G Dal Bello  1 , K Meyer  2 , J Roder  2 , H Roder  2 , J Grigorieva  2
Affiliations
Observational Study

Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy

F Grossi et al. Br J Cancer. .

Abstract

Background: VeriStrat is a blood-based proteomic test with predictive and prognostic significance in second-line treatments for non-small cell lung cancer (NSCLC). This trial was designed to investigate the role of VeriStrat in first-line treatment of advanced NSCLC with standard chemotherapy. Here we present the results for 76 non-squamous patients treated with a combination of carboplatin or cisplatin with pemetrexed.

Methods: The test-assigned classifications of VeriStrat Good or VeriStrat Poor to samples collected at baseline. The primary end point was progression-free survival (PFS); secondary end points included overall survival (OS) and objective response. Exploratory analyses of end points separately in carboplatin/pemetrexed and cisplatin/pemetrexed subgroups were also conducted.

Results: Patients classified as VeriStrat Good had longer PFS and OS than VeriStrat Poor: 6.5 vs 1.6 months and 10.8 vs 3.4 months, respectively; the corresponding hazard ratios (HRs) were 0.36 (P<0.0001) and 0.26 (P<0.0001); they were also more likely to achieve objective response. Prognostic significance of VeriStrat was confirmed in multivariate analysis. Significant differences in OS and PFS between Veristrat classifications were also found when treatment subgroups were analysed separately.

Conclusions: The trial demonstrated clinical utility of VeriStrat as a prognostic test for standard first-line chemotherapy of non-squamous advanced NSCLC.

PubMed Disclaimer

Conflict of interest statement

Julia Grigorieva, Krista Meyer, Joanna Roder, and Heinrich Roder are employees of Biodesix and hold company options. Francesco Grossi was compensated as a speaker for Eli Lilly, Bristol-Myers-Squibb, and received fees for participating in sponsored meetings and advisory boards of Bristol-Myers-Squibb. Carlo Genova received personal fees from Bristol-Myers-Squibb. The remaining authors declare no conflict of interest.

Figures

Figure 1
Figure 1
CONSORT diagram. Abbreviations: Cis/Pem=Cisplatin/Pemetrexed; Carbo/Pem=Carboplatin/Pemetrexed.
Figure 2
Figure 2
Kaplan–Meier curves of PFS and OS. (A) Progression-free survival by VeriStrat in overall population. (B) Overall survival by VeriStrat in overall population. (C) Progression-free survival by VeriStrat in treatment subgroups. (D) Overall survival by VeriStrat in treatment subgroups. Abbreviations: VSG=VeriStrat Good; VSP=VeriStrat Poor.
See this image and copyright information in PMC

References

    1. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, Radosavljevic D, Paccagnella A, Zatloukal P, Mazzanti P, Bisset D, Rosell R (2007) Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 99(11): 847–857. - PubMed
    1. Azuma K, Komohara Y, Sasada T, Terazaki Y, Ikeda J, Hoshino T, Itoh K, Yamada A, Aizawa H (2007) Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 98(9): 1336–1343. - PMC - PubMed
    1. Carbone DP, Ding K, Roder H, Grigorieva J, Roder J, Tsao MS, Seymour L, Shepherd FA (2012) Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial. J Thorac Oncol 7(11): 1653–1660. - PMC - PubMed
    1. Carbone DP, Salmon JS, Billheimer D, Chen H, Sandler A, Roder H, Roder J, Tsypin M, Herbst RS, Tsao AS, Tran HT, Dang TP (2010) VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer 69(3): 337–340. - PMC - PubMed
    1. Chung CH, Seeley EH, Roder H, Grigorieva J, Tsypin M, Roder J, Burtness BA, Argiris A, Forastiere AA, Gilbert J, Murphy B, Caprioli RM, Carbone DP, Cohen EE (2010) Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol Biomarkers Prev 19(2): 358–365. - PMC - PubMed

Publication types

MeSH terms